Get started
Author

M. Alper Kursunel

Observed names: KURŞUNEL, MUAMMER ALPER, Kursunel, Muammer A., M Alper Kursunel, M.A. Kursunel, Muammer A. Kursunel
Observed institutions: Max Delbrück Center, Hacettepe University Hospital, Berlin-Brandenburger Centrum für Regenerative Therapien, Immatics Biotechnologies (Germany), Hacettepe University, Charité – Universitätsmedizin Berlin
ORCID: 0000-0002-2483-1920
Observed ORCID: 0000-0002-2483-1920
OpenAlex ID: A5018695217
The untold story of IFN-γ in cancer biology
2016 · M. Alper Kursunel, Gunes Esendagli · Cytokine & Growth Factor Reviews · 198
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 89
Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression
2015 · Alberto Sada Japp, M. Alper Kursunel, et al. · Cancer Immunology Immunotherapy · 69
Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes
2021 · M. Alper Kursunel, Ekim Z. Taskiran, et al. · Cancer Immunology Immunotherapy · 42
PDF
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
2024 · Martin Wermke, Tobias A W Holderried, et al. · Journal for ImmunoTherapy of Cancer · 36
Design and in vitro evaluation of folate-targeted, co-drug encapsulated theranostic liposomes for non-small cell lung cancer
2020 · Merve Karpuz, Mine Silindir-Gunay, et al. · Journal of Drug Delivery Science and Technology · 33
Tumor-Induced Myeloid Cells Are Reduced by Gemcitabine-Loaded PAMAM Dendrimers Decorated with Anti-Flt1 Antibody
2018 · Digdem Yoyen-Ermis, Kivilcim Ozturk, et al. · Molecular Pharmaceutics · 23
A Co-Inhibitory Alliance in Myeloid Leukemia: TIM-3/Galectin-9 Complex as a New Target for Checkpoint Blockade Therapy
2017 · M. Alper Kursunel, Gunes Esendagli · EBioMedicine · 14
PDF
Anticancer activity of thymoquinone in non-small cell lung cancer and possible involvement of PPAR- γ pathway
2025 · Mehmet Gurbilek, Cigdem D. Deniz, et al. · International Journal of Radiation Biology · 11
1600O Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a phase I trial
2025 · S.P. Patel, A.M. Tsimberidou, et al. · Annals of Oncology · 10
Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 9
PDF
Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.
2025 · Martin Wermke, Winfried Alsdorf, et al. · Journal of Clinical Oncology · 7
PDF
687 ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients
2024 · Martin Wermke, Winfried Alsdorf, et al. · Journal for ImmunoTherapy of Cancer · 5
Proerythroblast Cells of Diamond-Blackfan Anemia Patients With RPS19 and CECR1 Mutations Have Similar Transcriptomic Signature
2021 · Beren Karaosmanoglu, M. Alper Kursunel, et al. · Frontiers in Physiology · 5
PDF
Corrigendum to “The untold story of IFN-γ in cancer biology” [Cytokine Growth Factor Rev. 31 (2016) 73–81]
2017 · M. Alper Kursunel, Gunes Esendagli · Cytokine & Growth Factor Reviews · 5
Liver resection modulates hepatic chemokine levels in breast cancer
2023 · Hilmi Anil Dincer, Utku Horzum, et al. · Surgery · 3
Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy.
2026 · Diwakar Davar, Sapna Pradyuman Patel, et al. · Journal of Clinical Oncology · 2
590 A first-in-human, phase 1 trial of IMA203 PRAME-directed TCR T-cell therapy with PRAME-encoding mRNA-4203 in previously treated, unresectable or metastatic cutaneous melanoma or synovial sarcoma
2025 · James W Smithy, Rodabe N Amaria, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
579 Quality of starting material result in high manufacturability and favorable product phenotype of IMA203, a PRAME-directed TCR T-cell therapy
2025 · M Alper Kursunel, Brent Chesson, et al. · Journal for ImmunoTherapy of Cancer
PDF
360 Combination of a TCR-engineered autologous PRAME-targeting T cell therapy with a PRAME-encoding mRNA for the treatment of solid tumors
2024 · Fabian Brunk, Rafael Blasco Patino, et al. · Journal for ImmunoTherapy of Cancer
Interactıon Mechanısms Between Small Cell Lung Cancer Cells And T Lymphocytes
2019 · M. Alper Kursunel · Hacettepe University Institutional Repository (hacettepe.edu.tr)
PDF
Hypocrisy Of Hodgkin’s Lymphoma Cells In Immunomodulation of T Cells Regardless to Comparable Expression Of B7 Costimulatory Molecules
2019 · ESENDAĞLI, GÜNEŞ, üner, aylin, et al. · Bursa Uludag University - AVESIS
Gemcitabine delivery via dendrimer carriers decorated with anti-VGFR1 antibody to target tumor-induced myeloid cells.
2018 · ESENDAĞLI, GÜNEŞ, ÇALIŞ, SEMA, et al. · Bursa Uludag University - AVESIS
Farklı tümör modellerinin deney farelerinde geliştirilmesi ve optimizasyonu
2017 · YÖYEN ERMİŞ, DİĞDEM, ESENDAĞLI, GÜNEŞ, et al. · Bursa Uludag University - AVESIS
EIncreased monocytic myeloid-derived suppressor cells in small-cell lung cancer implicate interaction between small cell lung cancer cells and monocytes
2017 · ESENDAĞLI, GÜNEŞ, ESENDAĞLI, DORİNA, et al. · Bursa Uludag University - AVESIS
Works count: 28
Citation count: 563
H-index: 10
I10-index: 10
Year
Topic
Type